Document is current
Any future updates will be listed below
-
Authors
Nelson, Barnaby
Shenton, Martha E. https://orcid.org/0000-0003-4235-7879
Woods, Scott W. https://orcid.org/0000-0002-3103-5228
,
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U24MH124629, U01MH124631, and U01MH124639, U24MH124629, U01MH124631, and U01MH124639, U24MH124629, U01MH124631, and U01MH124639)
Wellcome Trust (220664/Z/20/Z and 220664/A/20/Z, 220664/Z/20/Z and 220664/A/20/Z)
- License Information
-
More Information
Article History
Received: 16 February 2025
Accepted: 20 February 2025
First Online: 15 April 2025
Competing interests
: S.W.W. has received sponsor-initiated research funding support from Boehringer-Ingelheim, Amarex, and SyneuRx. He has been a paid consultant to Boehringer-Ingelheim, New England Research Institute, and Takeda. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. All other authors have nothing to disclose.
